A PYMNTS Company

China: Regulator fines US medical firm for price-fixing

By  |  December 8, 2016

A Chinese regulator has fined a local unit of US-listed medical device firm Medtronic $17.20 million for price fixing, the National Development and Reform Commission said in a statement on Wednesday.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The state planner said it had fined Medtronic (Shanghai) Management Co following an investigation into monopolistic behavior related to the firm’s cardiovascular and diabetes medical device products.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    The NDRC said Medtronic had carried out monopolistic behavior with its distributors and local partners to fix prices and set lower limits on the resale price to hospitals.

    “We can confirm that Medtronic was investigated by China’s National Development and Reform Commission (NDRC) related to the country’s anti-monopoly law, and Medtronic accepts the NDRC’s decision,” a company spokesman said in emailed comments.

    “We are absolutely committed to ensuring that we are in full compliance with local laws and regulations.”

    China has fined car makers, drug manufacturers and white goods firms over the last year for price fixing, while medical device makers came under the spotlight as far back as 2013.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.